Kala Bio (KALA) Net Margin (2019 - 2022)
Kala Bio (KALA) posted Net Margin of 6922.14% for Q3 2022, up 617.11% sequentially from 1338.62% in Q2 2022, and up 783923.0% YoY from N/an in Q3 2021.
Kala Bio (KALA) Net Margin (2019 - 2022) Analysis & Trends
Kala Bio has reported Net Margin for 4 years, with the latest figure at 6922.14% in Q3 2022.
- Quarterly Net Margin rose 783923.0% year-over-year to 6922.14% in Q3 2022, while the trailing twelve-month figure through Dec 2022 was 1151.64% (up 11708.0% YoY) and the FY2022 annual result came in at 1151.64%, up 11708.0% from the prior year.
- Net Margin advanced to 6922.14% in Q3 2022 per KALA's latest filing, from 1338.62% in the prior quarter.
- Over five years, Net Margin peaked at 6922.14% in Q3 2022 and troughed at 2798.56% in Q2 2020.
- A 4-year average of 1091.37% and a median of 1390.17% in 2020 frame the typical range for Net Margin.
- The sharpest annual moves came in 2020 and 2022: Net Margin slumped 164032 bps in 2020, then soared 783923 bps in 2022.
- Over 4 years, Net Margin stood at 1860.85% in 2019, then grew by 25 bps to 1390.17% in 2020, then slumped by 84 bps to 2562.93% in 2021, then surged by 370 bps to 6922.14% in 2022.
- According to Business Quant data, Net Margin over the past three periods registered 6922.14%, 1338.62%, and 2400.95% for Q3 2022, Q2 2022, and Q1 2022 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.83 Bn | 130.98 Bn | 2.84 Bn | 32.99% |
| 2 | Regeneron Pharmaceuticals | 85.79 Bn | 77.79 Bn | 3.93 Bn | 30.23% |
| 3 | Argenx Se | 64.95 Bn | 59.77 Bn | 1.37 Bn | 31.16% |
| 4 | Moderna | 58.59 Bn | 53.46 Bn | 52.00 Mn | -539.31% |
| 5 | BeOne Medicines | 41.93 Bn | 36.83 Bn | 1.53 Bn | 13.90% |
| 6 | Alnylam Pharmaceuticals | 31.52 Bn | 28.21 Bn | 992.69 Mn | 12.74% |
| 7 | BioNTech SE | 27.98 Bn | 9.58 Bn | 668.28 Mn | -16.51% |
| 8 | Insmed | 27.42 Bn | 26.26 Bn | 358.27 Mn | -3.12% |
| 9 | Royalty Pharma | 27.33 Bn | 26.49 Bn | - | 12.09% |
| 10 | Kala Bio | 10.00 Mn | 10.00 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2022 | 6,922.14% |
| Jun 30, 2022 | -1,338.62% |
| Mar 31, 2022 | -2,400.95% |
| Dec 31, 2021 | -2,562.93% |
| Sep 30, 2021 | -917.09% |
| Jun 30, 2021 | -1,196.26% |
| Mar 31, 2021 | -931.17% |
| Dec 31, 2020 | -1,390.17% |
| Sep 30, 2020 | -1,258.92% |
| Jun 30, 2020 | -2,798.56% |
| Mar 31, 2020 | -2,049.95% |
| Dec 31, 2019 | -1,860.85% |
| Sep 30, 2019 | -1,597.24% |
| Jun 30, 2019 | -1,158.24% |
| Mar 31, 2019 | -1,831.75% |